LAVA Medtech Acquisition registered to offer 10 million units to be priced at $10 each. A unit consists of one share of Class A common stock and one-half of a warrant.
The SPAC’s acquisition focus is on companies within the healthcare and healthcare-related industries, primarily in the United States and Canada.
LAVA Medtech is led by CEO and Director Dr. Anthony Natale, who has been a managing partner at Aperture Venture Partners since 2010.
RBC Capital Markets is managing the offering. The underwriters have an option to purchase up to an additional 1.5 million units to cover any over-allotments.
The SPAC will apply for a Nasdaq listing under LVACU. Read more.